Pharmaceutico-Analytical Study of Muktashukti Pishti and Muktashukti bhasma and Comparative Evaluation of their Relative Oral Bioavailability

Abstract

Background: Shukti (Oyster) is a very commonly occurring calcium form. It is rich source of calcium & minerals. As per text it can be converted into two forms which are bhasma (calcinated ash) and pishti (powdered form without agni).These forms may have different rate of absorption. This needs to be studied. Aim: To study Pharmaceutico-analytical study of Muktashukti pishti & Muktashukti bhasma and comparative evaluation of their relative oral bioavailability. Materials and methods: The two formulations will be prepared from shukti (oyster). By triturating with Gulabjala Muktashukti pishti will be prepared and by traditional puta method Muktashukti bhasma will be prepared. The prepared formulations will be assessed for Bhasma Pariksha mentioned in Ayurveda. Organoleptic characters, physicochemical parameters and Particle size distribution analysis, SEM-EDX (Scanning Electron Microscopy, Energy Dispersive X-Ray Analysis), FTIR (Fourier-transform infrared spectroscopy), XRD (X-Ray Diffraction), GCMS (Gas Study Protocol Kamble et al.; JPRI, 33(31B): 1-9, 2021; Article no.JPRI.68599 2 Chromatography Mass Spectrometry) will be evaluated. To assess the relative oral bioavailability of Muktashukti pishti & Muktashukti bhasma study will be conducted in healthy volunteers and will be compared with the standard calcium supplement. The study will be conducted in between two test groups and standard group. Observation and results: The analytical parameters will be assessed and compared in Muktashukti bhasma and Muktashukti pishti. For relative oral bioavailability Blood serum calcium will be assessed in all three groups. By applying unpaired "t" Test, One-way ANOVA the statistical significance can be measured. Conclusion: The pharmaceutical & analytical study of Muktashukti pishti and Muktashukti bhasma will provide the standard parameters and clinical comparative evaluation with standard will generate evidence for better bioavailability.

Full text

_____________________________________________________________________________________________________
*Corresponding author: E-mail: wanjarias@rediffmail.com;
Journal of Pharmaceutical Research International
33(31B): 1-9, 2021; Article no.JPRI.68599
ISSN: 2456-9119
(Past name: British Journal of Pharmaceutical Research, Past ISSN: 2231-2919,
NLM ID: 101631759)
Pharmaceutico-Analytical Study of Muktashukti
Pishti and Muktashukti bhasma and Comparative
Evaluation of their Relative Oral Bioavailability
Shweta Kamble
1
, Anita Wanjari
1*
, Bharat Rathi
1
and D. Rajput
1
1
Department of Rasashastra and Bhaishajya Kalpana, Mahatma Gandhi Ayurveda College Hospital
and Research Centre, Salod (H) Wardha, Datta Meghe Institute of Medical Sciences (Deemed to be
University) Wardha, Maharashtra, India.
Authors’ contributions
This work was carried out in collaboration between all authors. Author SK designed the study,
performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript.
Author AW managed the analyses of the study. Authors BR and DR managed the literature
searches. All authors read and approved the final manuscript.
Article Information
DOI: 10.9734/JPRI/2021/v33i31B31680
Editor(s):
(1) Dr. Paola Angelini, University of Perugia, Italy.
Reviewers:
(1) Damineni Saritha, Sultan Ul Uloom College of Pharmacy, JNTUH, India.
(2) Marcelo Antonio de Oliveira, Federal University of Espirito Santo, Brazil.
Complete Peer review History:
http://www.sdiarticle4.com/review-history/68599
Received 16 March 2021
Accepted 22 May 2021
Published 11 June 2021
ABSTRACT
Background:
Shukti (Oyster) is a very commonly occurring calcium form. It is rich source of
calcium & minerals. As per text it can be converted into two forms which are bhasma (calcinated
ash) and pishti (powdered form without agni).These forms may have different rate of absorption.
This needs to be studied.
Aim: To study Pharmaceutico-analytical study of Muktashukti pishti & Muktashukti bhasma and
comparative evaluation of their relative oral bioavailability.
Materials and methods: The two formulations will be prepared from shukti (oyster). By triturating
with Gulabjala Muktashukti pishti will be prepared and by traditional puta method Muktashukti
bhasma will be prepared. The prepared formulations will be assessed for Bhasma Pariksha
mentioned in Ayurveda. Organoleptic characters, physicochemical parameters and Particle size
distribution analysis, SEM-EDX (Scanning Electron Microscopy, Energy Dispersive X-Ray
Analysis), FTIR (Fourier-transform infrared spectroscopy), XRD (X-Ray Diffraction), GCMS (Gas
Study Protocol

Kamble et al.; JPRI, 33(31B): 1-9, 2021; Article no.JPRI.68599
2
Chromatography Mass Spectrometry) will be evaluated. To assess the relative oral bioavailability of
Muktashukti pishti & Muktashukti bhasma study will be conducted in healthy volunteers and will be
compared with the standard calcium supplement. The study will be conducted in between two test
groups and standard group.
Observation and results: The analytical parameters will be assessed and compared in
Muktashukti bhasma and Muktashukti pishti. For relative oral bioavailability Blood serum calcium
will be assessed in all three groups. By applying unpaired “t” Test, One-way ANOVA the statistical
significance can be measured.
Conclusion: The pharmaceutical & analytical study of Muktashukti pishti and Muktashukti bhasma
will provide the standard parameters and clinical comparative evaluation with standard will
generate evidence for better bioavailability.
Keywords: Muktashukti pishti; muktashukti bhasma, analysis; bioavailability.
1. INTRODUCTION
Rasashastra & Bhaishajya Kalpana is one
among the branches of Ayurveda, which deals
with Ayurvedic pharmaceutics. Rasashastra
deals with pharmaceutical preparation of
Ayurveda related to metallic origin [1]. Most
emphasis is given with respect to the therapeutic
uses of mercurial, mineral and metallic medicines
including calcium containing formulations
specified for various disease conditions [2].
Bhasma is a metallic or mineral preparation
treated with specific liquid which are mostly juice,
decoction or urine of animals & then exposed to
quantum of heat according to their suitable
properties known as puta. It is an ash obtained
through incineration. The raw material undergoes
an elaborate process of purification (shodhan)
followed by maran. The end product i.e. bhasma
is expected to be a non-toxic material which can
be readily absorbed & assimilated.
Pishti is a fine powder of medicine that absorbs
in body easily and possess similar efficacy like
that of bhasma. The same purified drug can be
used for making pishti as used for making
bhasma but there is difference in preparation
method and their potency. Pishti also has quick
absorption and assimilation because of micro-
fine particles like bhasma [3]. Use of metallic &
mineral preparations for maintaining health
&curing diseases is a unique feature of rasa
shashtra. Sudhavarga dravya are grouping of
drugs that possess high calcium content. It
includes Shankha, Shukti, Pravala, Godanti,
Dugdhapashan, Samudraphena, and
Mrudgarshrunga [4].
Calcium is a trace element that every living
organism need. It is the most essentialnutrient in
the human body [5]. Human needs calcium to
building & maintaining strong bones & 99% of the
body calcium is present in the bones & teeth. It is
also useful for maintaining healthy
communication between the brain & body parts.
It has very essential role in physiological function
of regulation of gastro intestinal secretions,
muscular movement, bone structure and cardiac
physiology [6].
Shukti is a readily available & most cost-effective
drug from sudhavarga. Muktashukti and
jalashukti are the two types of shukti.
Muktashukti is the outer hard covering shell of
mukta. This provides mukta protection, nutrition
and structural frame for its survival and hence
called by synonyms muktagriha, muktamata and
muktamandira. The shukti which not contain
mukta or Mollusa into it and which is obtained
from sea is called as jalashukti. Shukti is an
source of various elements like zinc, iron,
calcium, selenium as well as vitamin A and
vitamin B12; dietary supplements may contain
calcium carbonate from it [7]. “Shuktija yoga” is
mention in visarpachikitsa externally for pradeha
[8]. It is used in netraroga for anjana karma [9].
Shukti in many formulations cures diseases like
shoola, amlapitta, grahani etc [10]. Ayurved
prakash explain shukti in the preparation of
“kshara bandha” [11]. Muktashukti bhasma is
having cooling effect. It is useful in Heart disease
and giving strength to brain it is useful in pittaj
vyadhi, fever & flatulence [12]. Muktashukti pishti
reduce excess pitta and heat due to its sheeta
virya. It is beneficial in heart burn, abdominal
pain, anorexia, calcium deficiency etc.
The analytical study & the therapeutic efficacy of
the drug is already mentioned and established
with research studies but, the Muktashukti pishti
& Muktashukti bhasma may differ in the
analytical parameters. However, same material
undergoes different pharmaceutical methods to
obtain different end product, may shows

Kamble et al.; JPRI, 33(31B): 1-9, 2021; Article no.JPRI.68599
3
difference in bioavailability & thus therapeutic
efficacy also. Considering this the study has
been planned to assess the relative oral
bioavailability of Muktashukti pishti & Muktashukti
bhasma along with standard calcium
supplement.
For all life stages Calcium is very essential
compound. Sudhavargadravya possess high
calcium content. Out of which Shukti is easily
available & cheap source. Pharmaceutico-
analytical study of the Muktashukti pishti &
Muktashukti bhasma was performed in previous
works but the bioavailability study of these both
formulations was not done. However, their
therapeutic efficacy may vary as per method of
preparation. Considering this, the study is
planned with development of standard operating
process and for their relative oral bioavailability
with standards. The drug given through oral route
appears in some quantity only, in the blood
plasma [13]. In this study the plasma
concentration will be assessed in all three
groups. Out of these herbo-mineral calcium
supplements, one which shows significant
bioavailability with that of standard calcium
supplement, can be used safely without giving
any side effects as standard calcium supplement
shows side effects like constipation & abdominal
discomfort.
2. MATERIALS AND METHODS
Study design: Randomized single blind
controlled study
Sample size: The sample size calculation for a
bioavailability and bioequivalent study is
dependent on multiple factors like power, intra
subject coefficient of variation, expected
geometric mean ratio.
According to C. Bhupati and V.H. Vajjha.
(STATISTICA, anno LXXVII, n.1, 2017), power of
85% would be reasonable for bioavailability study
to conduct on healthy volunteers. By considering
the values of Lower Bound (LL) =0.80, Upper
bound (UL) = 1.25, Alpha=0.05, Geo Mean Ratio
(GMR) = 0.947, Coefficient of Variation (CV) =
0.239 as fixed, the sample size can be calculated
as below.
Pharmaceutical study: pharmaceutical
preparation of Muktashukti bhasma &
Muktashukti pishti will be prepared. It will be
done by following steps.
I) Procurement and Authentication of Raw
materials:
1. Shukti will be procured from Shri Shaila
Agency, Nagpur and will be authenticated
by the Department of Rasashashtra
(MGACH & RC).
2. Kumari & Gulabpushpa will be collected
from medicinal plants garden (MGACH &
RC), and primarily Authenticated by
Dravyaguna Department.
3. Kanji & Gulabjal will be prepared in
Dattatraya Rasashala which is required for
Shodhan of Mukta shukti & preparation of
Muktashukti pishti respectively.
II) Shodhana (purification) of Shukti: [14]
Small pieces of shukti will be made with the help
of mortar & pestle
These pieces will tied in a clean cloth to make a
pottali
The potalli will be subjected to swedan in vessel
containing kanji for 3 hrs (1 yam)
After it shukti pieces will be washed with warm
water & dried.
III) Preparation of Muktashukti pishti [15]
Shodhita muktashukti will be pounded in khalva
yantra
Triturating will be done in khalva yantra till 21
days by adding Gulabjala into it.
IV) Marana (incineration) of Shukti: [16]
Shodhit shukti pieces will be crushed again in a
khalvayantra
Kumari swarasa will be added into it to make a
paste
Chakrika will be made from it & allowing to dry
Prepared chakrika will be kept in sarava

Kamble et al.; JPRI, 33(31B): 1-9, 2021; Article no.JPRI.68599
4
Sandhi lepan will be done and allowing to dry the
sarava
Then it will be subjected to heating for giving one
gajaputa till sidhi pariksha attains.
Analytical study: For analytical study
organoleptic characters and physicochemical
parameters and other sophisticated tests like
Particle size distribution analysis, SEM –EDX,
FTIR, XRD, and GCMS will be done [17].
Study Parameters [18]
Analytical study: Under analytical study the
organoleptic study will be performed under
following heads by using the sense organs
 Specifications –
a. Colour
b. Odour
c. Taste
d. Touch
• Physico-Chemical analysis
1. pH(10% aqueous extract)
2. Loss on drying at 105
0
C
3. Ash value analysis under this , Total ash
value , Water soluble ash and Acid-
insoluble ash will be analysed
4. Water soluble extractive values and
alcohol soluble extractive values will be
calculated
Sophisticated Instrumental analysis
1. Particle size distribution analysis
2. SEM –EDX
3. FTIR
4. XRD
5. GCMS
Bioavailability study: It will be randomized
single blinded study in which 30 healthy
Volunteers in each group will be selected (total
90 volunteers) from Swastharakshan OPD,
Mahatma Gandhi Ayurvedic College Hospital and
Research Centre, salod (H), Wardha.
Eligibility criteria: Age group from 20 to 40
years of volunteers will be taken in the study.
The screening parameters for this will be
physical examination and complete blood count
(CBC), blood sugar, liver function test, Kidney
function test, lipid profile, blood pressure. The
volunteers with normal values will be selected for
the study.
Interventions: In total 90 volunteers one group
with 30 volunteers will be standard group in
which standard Calcium supplement were given
500mg once a day before meal, second group
with 30 volunteers Muktashukti pishti will be
given 500mg once a day before meal and the
third group with 30 volunteers Muktashukti
bhasma will be given 500mg once a day before
meal. The study will be conducted for 15 days.
Investigation during treatment: Complete
blood count, Liver Function test, Kidney Function
test, Lipid profile, Blood sugar, Urine routine and
microscopic, Blood Serum Calcium level will be
done for screening.
Criteria for discontinuing or modifying
allocated interventions: If patient having any
problem related to consumption of medicine or
having any sensitivity will be withdraw from
study.
Follow up period after treatment: After 24
hours, 3
rd
day, 7
th
day, 15
th
day of drug
administration.
Implementation: Principal invigilator will allocate
and enroll the patient.
Observation & Results: The pharmaceutically
prepared Muktashukti pishti and Muktashukti
bhasma will be analyzed for organoleptic
parameters and physichochemical parameters.
The parameters will be compared. The
sophisticated instrumental analysis, SEM –EDX,
FTIR, XRD and GCMS of Muktashukti pishti and
Muktashukti bhasma will be done and compared
as per the results obtained.
Table 1. The sample size and power
The sample size and power
Sample 54 50 47 44 35 30 26 24
Power 97.9 97.0 96.0 95.0 90.0 85.0 80.0 76.6

Kamble et al.; JPRI, 33(31B): 1-9, 2021; Article no.JPRI.68599
5
Table 2. Dose and frequency
Sr
no
Group
Sample
size
Intervention
Dose &
frequency
Anupan
(Vehicle)
Duration
1. Standard
group
30
volunteers
Standard calcium
compound (SDC)
500mg (OD)
before meal
Water 15 days
2. Test group
1
30
volunteers
Muktashukti pishti
(MSP)
500mg (OD)
before meal
Water 15 days
3. Test group
2
30
volunteers
Muktashukti
bhasma (MSB)
500mg (OD)
before meal
Water 15 days
Table 3. Blood collection after administration of drug
Group
Blood collection after administration of drug
SDC 00 24 hrs 3
rd
day 7
th
day 15
th
day
MSP 00 24 hrs 3
rd
day 7
th
day 15
th
day
MSB 00 24 hrs 3
rd
day 7
th
day 15
th
day
Table 4. Coding of blood sample of Group SDC
The relative oral bioavailability of Muktashukti
pishti and Muktashukti bhasma in comparison
with standard calcium will be observed.
Statistical analysis: Statistical analysis will be
done by applying unpaired‘t’ Test & One-way
ANOVA. Unpaired t test will be applied for pre
and post assessment of Blood serum calcium.
One way ANOVA will be applied for assessment
of statistical significance related to Blood serum
calcium, in between three groups.
Group SDC(n=30)
Blood collection after administration of drug
00
24hrs
3
rd
day
7
th
day
15
th
day
SDC1 SDC1-00 SDC1-24 SDC1-3 SDC1-7 SDC1-15
SDC2 SDC2-00 SDC2-24 SDC2-3 SDC2-7 SDC2-15
SDC3 SDC3-00 SDC3-24 SDC3-3 SDC3-7 SDC3-15
SDC4 SDC4-00 SDC4-24 SDC4-3 SDC4-7 SDC4-15
SDC5 SDC5-00 SDC5-24 SDC5-3 SDC5-7 SDC5-15
SDC6 SDC6-00 SDC6-24 SDC6-3 SDC6-7 SDC6-15
SDC7 SDC7-00 SDC7-24 SDC7-3 SDC7-7 SDC7-15
SDC8 SDC8-00 SDC8-24 SDC8-3 SDC8-7 SDC8-15
SDC9 SDC9-00 SDC9-24 SDC9-3 SDC9-7 SDC9-15
SDC10 SDC10-00 SDC10-24 SDC10-3 SDC10-7 SDC10-15
SDC11 SDC11-00 SDC11-24 SDC11-3 SDC11-7 SDC11-15
SDC12 SDC12-00 SDC12-24 SDC12-3 SDC12-7 SDC12-15
SDC13 SDC13-00 SDC13-24 SDC13-3 SDC13-7 SDC13-15
SDC14 SDC14-00 SDC14-24 SDC14-3 SDC14-7 SDC14-15
SDC15 SDC15-00 SDC15-24 SDC15-3 SDC15-7 SDC15-15
SDC16 SDC16-00 SDC16-24 SDC16-3 SDC16-7 SDC16-15
SDC17 SDC17-00 SDC17-24 SDC17-3 SDC17-7 SDC17-15
SDC18 SDC18-00 SDC18-24 SDC18-3 SDC18-7 SDC18-15
SDC19 SDC19-00 SDC19-24 SDC19-3 SDC19-7 SDC19-15
SDC20 SDC20-00 SDC20-24 SDC20-3 SDC20-7 SDC20-15
SDC21 SDC21-00 SDC21-24 SDC21-3 SDC21-7 SDC21-15
SDC22 SDC22-00 SDC22-24 SDC22-3 SDC22-7 SDC22-15
SDC23 SDC23-00 SDC23-24 SDC23-3 SDC23-7 SDC23-15
SDC24 SDC24-00 SDC24-24 SDC24-3 SDC24-7 SDC24-15
SDC25 SDC25-00 SDC25-24 SDC25-3 SDC25-7 SDC25-15
SDC26 SDC26-00 SDC26-24 SDC26-3 SDC26-7 SDC26-15
SDC27 SDC27-00 SDC27-24 SDC27-3 SDC27-7 SDC27-15
SDC28 SDC28-00 SDC28-24 SDC28-3 SDC28-7 SDC28-15
SDC29 SDC29-00 SDC29-24 SDC29-3 SDC29-7 SDC29-15
SDC30 SDC30-00 SDC30-24 SDC30-3 SDC30-7 SDC30-15

Kamble et al.; JPRI, 33(31B): 1-9, 2021; Article no.JPRI.68599
6
3. DISCUSSION
Ayurveda formulations are becoming popular
throughout the world. Rising population, cost
effectiveness, less side effects, available at all
places are few remarkable causes regarding the
use of herbal and mineral drugs as a source of
medicines and health supplements [19]. With
growing importance, its safety and efficacy
studies must be conducted for global acceptance
[20].By incineration the bioavailability may be
increased and the drug action may be
potentiated. [21] The analysis of MSB and MSP
will be compared. In both the samples
organoleptic characters that is color, odor, taste
will be assessed. Particle size will be assessed,
which is a major parameter by means of which
rate of absorption can be assessed in MSB and
MSP. From scanning Electron Microscopy
Energy Dispersive X-Ray Analyzer (SEM EDX) is
elemental identification along with quantitative
composition can be finding out in MSB and MSP
[22]. By Fourier Transform Infrared Spectroscopy
(FTIR) chemical bonds will be identified in MSP
and MSB [23]. With the help of X-Ray Diffraction
(XRD) the crystalline structures of the molecule
will be recognized in both the samples that are
MSP and MSB [24]. GC-MS technique will be
used to analyze complex organic and
biochemical mixtures between MSP and MSB
[25]. Related studies of standardization of few
ayurvedic drugs were reported
[26,27].Pharmaceutico-analytical studies and
reviews by Khatib et. al. were reviewed
[28,29].The relative oral bioavailability between
MSP & MSB and standard calcium will be
assessed. The Herbo mineral formulations are
the most efficacious formulations [30]. However,
the assessment will be done by evaluation of
serum calcium in all of the three groups. The
plasma concentration of the serum calcium will
be plotted against time in all the three groups. It
is represented by the curve, known as area
under curve [31].
Table 5. Coding of blood sample of group MSP
Group MSP(n=30)
Blood collection after administration of drug
00
24hrs
3
rd
day
7
th
day
15
th
day
MSP1 MSP1-00 MSP1-24 MSP1-3 MSP1-7 MSP1-15
MSP2 MSP2-00 MSP2-24 MSP2-3 MSP2-7 MSP2-15
MSP3 MSP3-00 MSP3-24 MSP3-3 MSP3-7 MSP3-15
MSP4 MSP4-00 MSP4-24 MSP4-3 MSP4-7 MSP4-15
MSP5 MSP5-00 MSP5-24 MSP5-3 MSP5-7 MSP5-15
MSP6 MSP6-00 MSP6-24 MSP6-3 MSP6-7 MSP6-15
MSP7 MSP7-00 MSP7-24 MSP7-3 MSP7-7 MSP7-15
MSP8 MSP8-00 MSP8-24 MSP8-3 MSP8-7 MSP8-15
MSP9 MSP9-00 MSP9-24 MSP9-3 MSP9-7 MSP9-15
MSP10 MSP10-00 MSP10-24 MSP10-3 MSP10-7 MSP10-15
MSP11 MSP11-00 MSP11-24 MSP11-3 MSP11-7 MSP11-15
MSP12 MSP12-00 MSP12-24 MSP12-3 MSP12-7 MSP12-15
MSP13 MSP13-00 MSP13-24 MSP13-3 MSP13-7 MSP13-15
MSP14 MSP14-00 MSP14-24 MSP14-3 MSP14-7 MSP14-15
MSP15 MSP15-00 MSP15-24 MSP15-3 MSP15-7 MSP15-15
MSP16 MSP16-00 MSP16-24 MSP16-3 MSP16-7 MSP16-15
MSP17 MSP17-00 MSP17-24 MSP17-3 MSP17-7 MSP17-15
MSP18 MSP18-00 MSP18-24 MSP18-3 MSP18-7 MSP18-15
MSP19 MSP19-00 MSP19-24 MSP19-3 MSP19-7 MSP19-15
MSP20 MSP20-00 MSP20-24 MSP20-3 MSP20-7 MSP20-15
MSP21 MSP21-00 MSP21-24 MSP21-3 MSP21-7 MSP21-15
MSP22 MSP22-00 MSP22-24 MSP22-3 MSP22-7 MSP22-15
MSP23 MSP23-00 MSP23-24 MSP23-3 MSP23-7 MSP23-15
MSP24 MSP24-00 MSP24-24 MSP24-3 MSP24-7 MSP24-15
MSP25 MSP25-00 MSP25-24 MSP25-3 MSP25-7 MSP25-15
MSP26 MSP26-00 MSP26-24 MSP26-3 MSP26-7 MSP26-15
MSP27 MSP27-00 MSP27-24 MSP27-3 MSP27-7 MSP27-15
MSP28 MSP28-00 MSP28-24 MSP28-3 MSP28-7 MSP28-15
MSP29 MSP29-00 MSP29-24 MSP29-3 MSP29-7 MSP29-15
MSP30 MSP30-00 MSP30-24 MSP30-3 MSP30-7 MSP30-15

Kamble et al.; JPRI, 33(31B): 1-9, 2021; Article no.JPRI.68599
7
Table 6. Coding of blood sample of group MSB
Group MSB(n=30)
Blood collection after administration of drug
00
24hrs
3
rd
day
7
th
day
15
th
day
MSB1 MSB1-00 MSB1-24 MSB1-3 MSB1-7 MSB1-15
MSB2 MSB2-00 MSB2-24 MSB2-3 MSB2-7 MSB2-15
MSB3 MSB3-00 MSB3-24 MSB3-3 MSB3-7 MSB3-15
MSB4 MSB4-00 MSB4-24 MSB4-3 MSB4-7 MSB4-15
MSB5 MSB5-00 MSB5-24 MSB5-3 MSB5-7 MSB5-15
MSB6 MSB6-00 MSB6-24 MSB6-3 MSB6-7 MSB6-15
MSB7 MSB7-00 MSB7-24 MSB7-3 MSB7-7 MSB7-15
MSB8 MSB8-00 MSB8-24 MSB8-3 MSB8-7 MSB8-15
MSB9 MSB9-00 MSB9-24 MSB9-3 MSB9-7 MSB9-15
MSB10 MSB10-00 MSB10-24 MSB10-3 MSB10-7 MSB10-15
MSB11 MSB11-00 MSB11-24 MSB11-3 MSB11-7 MSB11-15
MSB12 MSB12-00 MSB12-24 MSB12-3 MSB12-7 MSB12-15
MSB13 MSB13-00 MSB13-24 MSB13-3 MSB13-7 MSB13-15
MSB14 MSB14-00 MSB14-24 MSB14-3 MSB14-7 MSB14-15
MSB15 MSB15-00 MSB15-24 MSB15-3 MSB15-7 MSB15-15
MSB16 MSB16-00 MSB16-24 MSB16-3 MSB16-7 MSB16-15
MSB17 MSB17-00 MSB17-24 MSB17-3 MSB17-7 MSB17-15
MSB18 MSB18-00 MSB18-24 MSB18-3 MSB18-7 MSB18-15
MSB19 MSB19-00 MSB19-24 MSB19-3 MSB19-7 MSB19-15
MSB20 MSB20-00 MSB20-24 MSB20-3 MSB20-7 MSB20-15
MSB21 MSB21-00 MSB21-24 MSB21-3 MSB21-7 MSB21-15
MSB22 MSB22-00 MSB22-24 MSB22-3 MSB22-7 MSB22-15
MSB23 MSB23-00 MSB23-24 MSB23-3 MSB23-7 MSB23-15
MSB24 MSB24-00 MSB24-24 MSB24-3 MSB24-7 MSB24-15
MSB25 MSB25-00 MSB25-24 MSB25-3 MSB25-7 MSB25-15
MSB26 MSB26-00 MSB26-24 MSB26-3 MSB26-7 MSB26-15
MSB27 MSB27-00 MSB27-24 MSB27-3 MSB27-7 MSB27-15
MSB28 MSB28-00 MSB28-24 MSB28-3 MSB28-7 MSB28-15
MSB29 MSB29-00 MSB29-24 MSB29-3 MSB29-7 MSB29-15
MSB30 MSB30-00 MSB30-24 MSB30-3 MSB30-7 MSB30-15
4. CONCLUSION
The conclusion will be drawn from the results
obtained and observations which will be
observed. The conclusions will content analytical
observations between MSB and MSP. For
relative oral bioavailability the maximum
concentration of calcium by plotting area under
curve (AUC) will be assessed between standard
calcium supplement tablet, MSP and MSB.
According the blood plasma concentration of
serum calcium, the graph will plotted against time
in all three groups. The drug with maximum area
under curve will be concluded as better relative
oral bioavailable.
CONSENT
It is not applicable.
ETHICAL APPROVAL
The study will be conducted on human
volunteers. The permission is obtained from the
related institutional ethical committee (IEC).The
approval reference number is
Ref.No.MGACHRC/IEC/July-2020/64.
COMPETING INTERESTS
Authors have declared that no competing
interests exist.
REFERENCES
1. Rathi B, Rathi R, Pusadkar S. Contribution
of text Rasapaddhati in the history of
Indian alchemy: A review. Journal of Indian
System of Medicine. 20191;7(2):72.
2. Mahulkar G, Rathi B. Pharmaceutical
Standardisation of Kukkutanda Tvak
Bhasma (Incinerated Egg Shell). Journal of
Research in Traditional Medicine.
2017;3(2):43-50.
3. Khedekar S, Patgiri BJ, Ravishankar B,
Prajapati PK. Standard manufacturing

Kamble et al.; JPRI, 33(31B): 1-9, 2021; Article no.JPRI.68599
8
process of Makaradhwaja prepared by
Swarna Patra–Varkha and Bhasma. Ayu.
2011;32(1):109.
4. Singh S, Kaur S, Baghel DS, Anand N,
Sabharwal S, Khanna V, Kumar A, Kaur I.
A Synoptic Overview on Ancient Alchemy
Sudha Varg (Calcium-Containing Drugs):
An applied Nanomedicine. InSmart
Nanotechnology with Applications. CRC
Press. 2020;189-224.
5. Pu F, et al. Calcium intake, Calcium
homeostasis and health. Food Science
and Human Wellness. 2016;5:8-16.
6. Dasari Srilakshmi TV Shalini Jain Smitha,
therapeutic potential of Sudha
vargadravyas vis-à-vis calcium compound:
A Review, International Research Journal
of Pharmacy. 2012;1.
7. Sharma S, Tarangini R. Motilal Banarasi
Das. Varanasi, edited by Kasinatha
Shastri, 11th edn, 11th edn, Taranga 12th,
Shloka17-19. 1979:287-8.
8. Pal D, Gurjar VK. Nanometals in Bhasma:
Ayurvedic Medicine. InMetal Nanoparticles
in Pharma Springer, Cham. 2017;389-415.
9. Acharya VY. Sushrut Samhita of Sushrut
with the Nibandhasangraha commentary of
Shri Dalhanacharya. Chikitsasthana.
2002;33:23-5.
10. Sharma S, Sharma 2nd G. Varanasi:
Chaukhambha Orientalia; 2012. Ashtanga
Sangraha. 2012;110.
11. Srilakshmi D, Shalini TV, Smitha J.
International Research Journal of
Pharmacy; 2012.
12. Raisuddin S. Ayurvedic bhasmas.
InScientific Basis for Ayurvedic Therapies
Routledge. 2003;107-124.
13. Wanjari AS, Pathak SS, Rajput D, Wanjari
DS, Jadhao S, Gokarn R. Effect of Piper
longum Linn on the oral bioavailability of
Phenytoin; 2003.
14. Gawalkar SS, Jadar PG. A Novel
Approach for Quality Control of the
Bhasmas of Mukta, Muktashukti, and
Shankha. Annals of Ayurvedic Medicine.
2017;6(3):98-105.
15. Khairnar B, Barve M, Khedekar S, Sawant
P. A Review on Pishti Kalpana. Journal of
Ayurveda and Integrated Medical
Sciences. 2017;2(2):212.
16. Panigrahi B, Ayu BP. Acute and Repeated
dose 28 day oral toxicity study of Bacnil
Capsule in albino rats; 2012.
17. Dubey N, Dubey N, Mehta RS, Saluja AK,
Jain DK. Physicochemical and
pharmacological assessment of a
traditional biomedicine: Mukta shouktic
bhasma. Songklanakarin Journal of
Science & Technology. 2009;1:31(5).
18. Wanjari AS, Magar S, Chapalgaokar S,
Chouragade NB, Wanjari DS. Evaluation
and Standardization of Herbal Formulation.
Research Journal of Pharmacognosy and
Phytochemistry. 2016;8(3):133.
19. Rathi B, Rathi R. Quantitative Analysis of
Medicinal plants used by the Traditional
healers of Karanja block of Wardha district
for treating Musculoskeletal disorders.
International Journal of Ayurvedic
Medicine. 2009;11(2):175-183.
20. Dukare P, Rathi B. Pharmaceutico-
Analytical Study Of shankhabhasma
Prepared By Two Different Methods And
Evaluation Of Its Relative Oral
Bioavailability In Healthy Volunteers.
European Journal of Molecular & Clinical
Medicine. 2020;7 (11).
21. Wadnerwar NN, Rajput DS, Deshmukh
AA, Gaikwad A. A Critical Review on
Haratala (An Arsenical Compound); 2020.
22. Leung YH, Guo MY, Ma AP, Ng AM,
Djurišić AB, Degger N, Leung FC.
Transmission electron microscopy artifacts
in characterization of the nanomaterial-cell
interactions. Applied microbiology and
biotechnology. 2017;101(13):5469-79.
23. Singh SK, Rai SB. Detection of
carbonaceous material in Naga Bhasma.
Indian journal of pharmaceutical sciences.
2012;74(2):178.
24. Bhardwaj R, Johar S, Kapila A, Sharma A.
Physicochemical study and quantitative
analysis swarna makshika bhasma.
International Journal of Pharmaceutical
and Biological Science Archive. 202;9(1).
25. Ibrahim WA, Sutirman ZA, Qaderi J, Bakar
KA, Basir SH, Aouissi IE. A review on
applications of gold and silver-based
sorbents in solid phase extraction and solid
phase microextraction. Malaysian Journal
of Analytical Sciences. 2020;24(4):464-83.
26. Gokarn, Rohit Ajith, Dhiraj Singh Rajput,
Pramod Yadav, Galib, Biswajyoti Patgiri,
and P. K. Prajapati. “Pharmaceutical
Standardization of Svarna Vanga.” Ancient
science of life. 2013;33(2):97–102.
Available: https://doi.org/10.4103/0257-
7941.139046.
27. Deogade, Meena Shamrao, KSR. Prasad.
“Standardization of Wild Krushnatulasi
(Ocimum Tenuiflorum Linn) Leaf.”
International Journal of Ayurvedic
Medicine. 2019;10(1): 52–61.

Kamble et al.; JPRI, 33(31B): 1-9, 2021; Article no.JPRI.68599
9
28. Khatib, Nazli, Shilpa Gaidhane, Abhay M.
Gaidhane, Mahanaaz Khatib, Padam
Simkhada, Dilip Gode, and Zahiruddin
Quazi Syed. “Ghrelin: Ghrelin as a
Regulatory Peptide in Growth Hormone
Secretion.” Journal of Clinical and
Diagnostic Research. 2014;8(8): MC13–
17.
Available:https://doi.org/10.7860/JCDR/20
14/9863.4767.
29. Khatib, Mahalaqua Nazli, Shilpa Gaidhane,
Abhay M. Gaidhane, Padam Simkhada,
and Zahiruddin Quazi Syed. “Ghrelin O
Acyl Transferase (GOAT) as a Novel
Metabolic Regulatory Enzyme.” Journal of
Clinical and Diagnostic Research.
2015;9(2): LE1–5.
Available:https://doi.org/10.7860/JCDR/20
15/9787.5514.
30. Gaikwad AV, Wadnerwar N, Chalakh S.
Therapeutic review of Herbo-mineral
Preparations with special reference to
Tribhuvankirti Rasa. Journal of Indian
System of Medicine. 2018;6(4):189.
31. Narayanan V, Pallewar S, Mane A,
Bhargava A. A randomized, volunteer,
pharmacokinetic study comparing
absorption and bioavailability of coral
calcium with calcium carbonate and
calcium citrate malate supplements; 2018.
© 2021 Kamble et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/68599